Making use of avacopan in clinical practice

Area of Science:

• Nephrology
• Rheumatology
• Immunology

Background:

• Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a severe autoimmune disease with frequent, progressive renal involvement.
• Standard therapy uses high-dose glucocorticoids (GCs) and cyclophosphamide/rituximab, but GCs cause significant morbidity.
• There is a critical need for glucocorticoid-sparing strategies in AAV management.

Purpose of the Study:

• To evaluate avacopan, a selective C5a receptor antagonist, as a novel therapeutic agent for AAV.
• To assess avacopan's efficacy and safety in achieving and sustaining remission compared to standard GC tapering.
• To determine avacopan's impact on renal recovery and GC-related toxicity.

Main Methods:

• The pivotal phase 3 ADVOCATE trial compared avacopan plus a standard GC regimen against a standard GC regimen alone.
• Efficacy was assessed by remission rates at 26 and 52 weeks.
• Safety, renal recovery, and GC-related toxicity were key secondary endpoints.

Main Results:

• Avacopan demonstrated non-inferior remission at 26 weeks and superior sustained remission at 52 weeks compared to standard GC taper.
• Avacopan significantly reduced GC-related toxicity and improved renal recovery, especially in patients with advanced kidney impairment.
• Real-world data since 2021 support avacopan's efficacy in diverse AAV subgroups, including severe renal disease.

Conclusions:

• Avacopan is an effective glucocorticoid-sparing option for inducing and maintaining remission in AAV.
• It offers improved renal outcomes and reduced treatment-related morbidity compared to standard GC therapy.
• Further research is needed to define long-term safety, optimal GC use, and avacopan's definitive role in AAV management.